← All candidates
155 insider filings on record.
155 filings on record.
RYTMRHYTHM PHARMACEUTICALS, INC.
NasdaqGM · Healthcare · $6.75B
$98.01
+1.28% · Sep 16
155 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 53 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$6.75B
Float
56.0M
81% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
28.1
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
150 more transactions on Pro →Context
Wall St
$139.47 avg target
+42.3% vs today · 15 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$0.83 act+$0.03
Q4 '25−$0.73 act+$0.05
Q3 '25−$0.82 act−$0.09
Q2 '25−$0.75 act−$0.08
Coverage
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?Insider Monkey · 06-30Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder?Insider Monkey · 06-22Rhythm Pharmaceuticals posts long-term setmelanotide data for obesityProactive · 06-16How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Updating Its Bardet-Biedl Diagnosis AlgorithmSimply Wall St. · 06-08
The file stays open
155 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice